Suppr超能文献

慢性肾脏病(CKD)患者血清巨噬细胞移动抑制因子(MIF)浓度升高与氧化应激及内皮激活标志物相关。

Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

作者信息

Bruchfeld Annette, Carrero Juan J, Qureshi Abdul R, Lindholm Bengt, Barany Peter, Heimburger Olof, Hu Maowen, Lin Xinchun, Stenvinkel Peter, Miller Edmund J

机构信息

Division of Renal Medicine, Karolinska University Hospital, Department of Clinical Science, Interventions and Technology (CLINTEC), Karolinska Institute, Stockholm, Sweden.

出版信息

Mol Med. 2009 Mar-Apr;15(3-4):70-5. doi: 10.2119/molmed.2008.00109. Epub 2009 Dec 8.

Abstract

Chronic kidney disease (CKD) carries an increased risk of cardiovascular disease (CVD). Macrophage migration inhibiting factor (MIF) is a proinflammatory cytokine implicated in the pathogenesis of sepsis, autoimmune disease, atherogenesis, and plaque instability, and is a known cardiac depressant. This post-hoc, cross-sectional study examined whether MIF serum concentrations are elevated in CKD patients. Our study included CKD 3-5 patients with moderate to severe renal dysfunction (n = 257) (mean age SD; 55 +/- 12 years) and 53 controls (60 +/- 12 years). Serum MIF concentrations, measured by enzyme-linked immunosorbent assay (ELISA), were studied in relation to glomerular filtration rate (GFR), presence of CVD, outcome and inflammatory and oxidative stress markers. MIF was significantly elevated in CKD patients compared with controls (CKD: median 676 [range 118-8275 pg/mL] controls: 433 [142-4707] pg/mL; P = 0.008). MIF was also associated with 8-hydroxy-2-deoxyguanosine (8-OH-dG) levels (rho = 0.26; P = 0.001), a marker of oxidative stress, and ICAM-1 levels (rho = 0.14; P = 0.02), a marker of endothelial activation. However, the elevated MIF concentrations were neither correlated with glomerular filtration rate (GFR) nor inflammatory markers such as CRP, IL-6, and TNF. When combining MIF and IL-6 as a marker of inflammation, a significant increase in risk for CVD was found, but when analyzing all-cause mortality, this did not differ significantly with regard to mortality from inflamed patients with low MIF levels. The data suggest that increased serum MIF levels found in CKD is not caused primarily by poor renal function, but is associated with markers of oxidative stress and endothelial activation and may play a role in vascular disease associated with CKD.

摘要

慢性肾脏病(CKD)会增加心血管疾病(CVD)的发病风险。巨噬细胞移动抑制因子(MIF)是一种促炎细胞因子,与脓毒症、自身免疫性疾病、动脉粥样硬化形成及斑块不稳定性的发病机制有关,并且是一种已知的心脏抑制因子。这项事后横断面研究调查了CKD患者血清中MIF浓度是否升高。我们的研究纳入了患有中度至重度肾功能不全的CKD 3 - 5期患者(n = 257)(平均年龄标准差;55±12岁)以及53名对照者(60±12岁)。通过酶联免疫吸附测定(ELISA)测量血清MIF浓度,并研究其与肾小球滤过率(GFR)、CVD的存在情况、预后以及炎症和氧化应激标志物之间的关系。与对照者相比,CKD患者的MIF显著升高(CKD:中位数676 [范围118 - 8275 pg/mL],对照者:433 [142 - 4707] pg/mL;P = 0.008)。MIF还与氧化应激标志物8 - 羟基 - 2 - 脱氧鸟苷(8 - OH - dG)水平(ρ = 0.26;P = 0.001)以及内皮激活标志物细胞间黏附分子 - 1(ICAM - 1)水平(ρ = 0.14;P = 0.02)相关。然而,升高的MIF浓度既与肾小球滤过率(GFR)无关,也与CRP、IL - 6和TNF等炎症标志物无关。当将MIF和IL - 6作为炎症标志物联合分析时,发现CVD风险显著增加,但在分析全因死亡率时,与低MIF水平的炎症患者相比,死亡率并无显著差异。数据表明,CKD患者血清MIF水平升高并非主要由肾功能不佳所致,而是与氧化应激和内皮激活标志物相关,并且可能在与CKD相关的血管疾病中起作用。

相似文献

5
Macrophage Migration Inhibitory Factor in Clinical Kidney Disease.临床肾脏病中的巨噬细胞移动抑制因子
Front Immunol. 2016 Jan 26;7:8. doi: 10.3389/fimmu.2016.00008. eCollection 2016.

引用本文的文献

本文引用的文献

1
The MIF receptor CD74 in diabetic podocyte injury.糖尿病足细胞损伤中的巨噬细胞移动抑制因子受体CD74
J Am Soc Nephrol. 2009 Feb;20(2):353-62. doi: 10.1681/ASN.2008020194. Epub 2008 Oct 8.
4
Macrophage migration inhibitory factor in cardiovascular disease.心血管疾病中的巨噬细胞移动抑制因子
Circulation. 2008 Mar 25;117(12):1594-602. doi: 10.1161/CIRCULATIONAHA.107.729125.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验